Celgene's Otezla gains US OK in psoriatic arthritis
This article was originally published in Scrip
Executive Summary
With the FDA on 21 March clearing Celgene's Otezla (apremilast) as the first oral therapy in the US to treat adults with active psoriatic arthritis, the company is ready to take on competitors Abbvie's Humira (adalimumab) and Amgen's Enbrel (etanercept) and Johnson & Johnson's drugs Stelara (ustekinumab) and Simponi (golimumab), which all must be injected subcutaneously, and Remicade (infliximab), which is administered by intravenous infusion.